Abstract
This review discusses the mineral bone disorders in patients with chronic kidney disease. We focus on the management of these conditions by administration of calcium, vitamin D (ergocalciferol and cholecalciferol), vitamin D receptor activators (calcitriol, alphacalcidiol), phosphate binders and calcimimetics (cinacalcet).
MeSH terms
-
Bone Density Conservation Agents / administration & dosage
-
Bone Density Conservation Agents / adverse effects
-
Bone Density Conservation Agents / metabolism*
-
Bone Diseases, Metabolic / diagnosis
-
Bone Diseases, Metabolic / drug therapy*
-
Bone Diseases, Metabolic / metabolism
-
Calcium / administration & dosage
-
Calcium / adverse effects
-
Calcium / metabolism*
-
Chronic Kidney Disease-Mineral and Bone Disorder / diagnosis
-
Chronic Kidney Disease-Mineral and Bone Disorder / drug therapy*
-
Chronic Kidney Disease-Mineral and Bone Disorder / metabolism
-
Diagnosis, Differential
-
Glomerular Filtration Rate
-
Humans
-
Hyperparathyroidism / diagnosis
-
Hyperparathyroidism / drug therapy
-
Hyperparathyroidism / metabolism
-
Osteoporosis / diagnosis
-
Osteoporosis / drug therapy
-
Osteoporosis / metabolism
-
Parathyroid Hormone / metabolism
-
Phosphates / administration & dosage
-
Phosphates / metabolism*
-
Renal Insufficiency, Chronic / diagnosis
-
Renal Insufficiency, Chronic / drug therapy*
-
Renal Insufficiency, Chronic / metabolism
-
Vitamin D / administration & dosage
-
Vitamin D / adverse effects
-
Vitamin D / metabolism*
Substances
-
Bone Density Conservation Agents
-
Parathyroid Hormone
-
Phosphates
-
Vitamin D
-
Calcium